Inhibition of BRD4 (and other BRD family members) by small molecule inhibitors of the BET family, such as the BET-bromodomain inhibitor JQ1, leads to preferential inhibition of c-MYC oncogene expression, growth arrest and extensive apoptosis in a variety of B-cell leukemia and lymphoma cell lines, including c-MYC/BCL2-double-hit DLBCLs and AML cells that overexpress c-MYC in association with BCL2 [398–401, 404]. Here, MYC is linked to lymphoma.